# KEYVIBE-008 (NCT05224141)

> Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

No report yet. It can be ordered.

- Drugs tested: MK-7684A
- Indication: first-line extensive-stage small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05224141
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Small Cell Lung Carcinoma
- Interventions: Pembrolizumab/Vibostolimab Co-Formulation; Saline placebo; Etoposide; Cisplatin; Atezolizumab; Carboplatin
- Enrollment: 460
- Primary outcome: Overall Survival (OS)

## Indexed commentary on KEYVIBE-008 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 8 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=keyvibe-008-nct05224141

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05224141", "email": "<work email>"}; the inbox owner confirms by the emailed link.